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Abstract
Background: The prediction of neurological outcome in comatose patients after cardiac arrest has major ethical
and socioeconomic implications. The purpose of this study was to assess the capability of serum neuron-specific
enolase (NSE), a biomarker of hypoxic brain damage, to predict death or vegetative state in comatose cardiac-
arrest survivors.
Methods: We conducted a prospective observational cohort study in one university hospital and one general
hospital Intensive Care Unit (ICU). All consecutive patients who suffered cardiac arrest and were subsequently
admitted from June 2007 to February 2009 were considered for inclusion in the study. Patients who died or awoke
within the first 48 hours of admission were excluded from the analysis. Patients were followed for 3 months or
until death after cardiopulmonary resuscitation. The Cerebral Performance Categories scale (CPC) was used as the
outcome measure; a CPC of 4-5 was regarded as a poor outcome, and a CPC of 1-3 a good outcome.
Measurement of serum NSE was performed at 24 h and at 72 h after the time of cardiac arrest using an enzyme
immunoassay. Clinicians were blinded to NSE results.
Results: Ninety-seven patients were included. All patients were actively supported during the first days following
cardiac arrest. Sixty-five patients (67%) underwent cooling after resuscitation. At 3 months 72 (74%) patients had a
poor outcome (CPC 4-5) and 25 (26%) a good outcome (CPC 1-3). The median and Interquartile Range [IQR] levels
of NSE at 24 h and at 72 h were significantly higher in patients with poor outcomes: NSE at 24 h: 59.4 ng/mL [37-
106] versus 28.8 ng/mL [18-41] (p < 0.0001); and NSE at 72 h: 129.5 ng/mL [40-247] versus 15.7 ng/mL [12-19] (p <
0.0001). The Receiver Operator Characteristics (ROC) curve for poor outcome for the highest observed NSE value for
each patient determined a cut-off value for NSE of 97 ng/mL to predict a poor neurological outcome with a
specificity of 100% [95% CI = 87-100] and a sensitivity of 49% [95% CI = 37-60]. However, an approach based on a
combination of SSEPs, NSE and clinical-EEG tests allowed to increase the number of patients (63/72 (88%))
identified as having a poor outcome and for whom intensive treatment could be regarded as futile.
Conclusion: NSE levels measured early in the course of patient care for those who remained comatose after
cardiac arrest were significantly higher in patients with outcomes of death or vegetative state. In addition, we
provide a cut-off value for NSE (> 97 ng/mL) with 100% positive predictive value of poor outcome. Nevertheless,
for decisions concerning the continuation of treatment in this setting, we emphasize that an approach based on a
combination of SSEPs, NSE and clinical EEG would be more accurate for identifying patients with a poor
neurological outcome.
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Despite improvement in resuscitation, the neurological
outcome of comatose patients after cardiac arrest
remains extremely poor [1]. Therefore, post-resuscita-
tion anoxic encephalopathy represents a common pro-
blem with ethical, social, and legal consequences. In
clinical practice, intensive care physicians are confronted
with the ethical question of whether to continue treat-
ment. In this context, providing predictors of poor out-
come (death or permanent vegetative state) with a
specificity of 100% could be useful for early identifica-
tion of irrecoverable patients for whom intensive treat-
ment could be regarded as futile and palliative care only
could be given.
Currently, several clinical parameters and electro-
encephalographic (EEG) patterns are recognised as
being strongly associated with a poor outcome in unse-
dated comatose survivors of cardiac arrest; these include
absence of pupillary or corneal reflexes, absence of
extensor motor response to pain 3 days after cardiac
arrest, myoclonus or epilepticus status within the first
day after resuscitation, and a burst-suppression or iso-
electric EEG pattern [1,2]. However, these clinical fea-
tures and EEG readings could be severely affected by
metabolic changes, therapeutic hypothermia or sedative
drugs, limiting their clinical relevance for supporting a
decision to withdraw active treatment. In contrast, bilat-
eral absence of early cortical response to Somatosen-
sory-Evoked Potentials (SSEPs) recorded on day 1 or
later after cardiac arrest accurately predicts a poor out-
come with 100% specificity, regardless of exam condi-
tions [2-7]. However, this electrophysiological procedure
is not routinely performed in all ICUs [8,9].
In this context, the serum Neuron-Specific Enolase
(NSE), a biomarker of hypoxic brain damage which can
be measured easily and reproducibly with minor inva-
siveness in patients, has recently been assessed as a
prognostic predictor after cardiac arrest in several stu-
dies [2,9-23]. However, the cut-off points for predicting
a poor outcome with no false positives vary greatly (9 to
91 ng/mL). Differences in definitions of poor outcome,
the duration of follow up, the timing of blood sampling
and assay procedures could explain these differences.
Therefore, we conducted a prospective cohort study to
assess the capability of NSE, measured at fixed times, to
predict a poor outcome (death or permanent vegetative
state) with certainty in a predefined post cardiac-arrest
comatose population.
Methods
Patients
We conducted a prospective cohort study of all conse-
cutive non trauma patients who suffered out-of- or in-
hospital cardiac arrest and were subsequently admitted
to the adult intensive care unit in the Caen University
Hospital and the Saint Lô General Hospital from June
2007 to February 2009. Patients who died or awoke
within the first 48 hours of admission were excluded
from this analysis. Therefore, only patients who
remained in coma at 48 hours after cardiac arrest were
included in the analysis. All patients were followed for
3 months after cardiac arrest or until death.
This study was submitted to the local ethics commit-
tee. The ethical board decided that approval was not
necessary given the observational nature of this prospec-
tive study. Thus, in accordance with French legislation
at the time of the study, no informed consent was
obtained from the patients.
Assessment of outcome
Neurological status at 3 months was assessed by tele-
phone interview for patients discharged alive from the
intensive care, using the 5-grade Glasgow-Pittsburgh
Cerebral Performance Category (GP-CPC) scale [24].
CPC 1:c o n s c i o u s ,a l e r t ,a n do r i e n t e dw i t hn o r m a lc o g -
nitive functions, CPC 2: conscious and alert with moder-
ate cerebral disability, CPC 3: conscious with severe
disability, CPC 4: comatose or in persistent vegetative
state, CPC 5: certified brain death or dead by traditional
criteria. A CPC score of 1-3 was considered a good out-
come and a CPC of 4-5 a poor outcome.
Measurement of serum NSE
Blood samples were collected at 24 h and 72 h after the
time of cardiac arrest. All samples with visible hemolysis
were discarded from analysis to avoid any falsely ele-
vated values for serum NSE. Blood was centrifuged at 3
000 rpm for 10 min. The isolated serum was immedi-
ately frozen at -80°C and stored until time of assay. The
serum NSE level was measured using a solid-phase
immunoassay with double monoclonal antibodies direc-
ted against NSE (Roche Diagnostics GmbH, Mannheim,
Germany) on an Elecsys instrument. The limit of detec-
tion was 0.05 ng/mL and the institutional normal value
was < 16.3 ng/mL. When the NSE level reached 50 ng/
mL, the serum was diluted to avoid a hook effect. Clini-
cians were blinded to NSE results during the entire
patient stay. For each patient, the highest measurement
of NSE was tested for outcome prediction. Because the
24 h value is more variable than that at 72 h, we also
considered the 72 h NSE value as the highest observed
NSE in the sensitivity analysis.
Data collection
Clinical variables collected at baseline were: age, sex,
underlying diseases, cause of the arrest (cardiac, respira-
tory, other or unknown), time between arrest and
cardiopulmonary resuscitation, initial cardiac rhythm
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rhythm), duration of cardiopulmonary resuscitation,
number of external electric shocks, cumulative epi-
nephrine dose, and scoring of disease severity within the
first day in ICU as assessed during admission by the
Simplified Acute Physiology Score type II (SAPS II) [25],
and number of organ failures according to Knaus cri-
teria [26].
Following our standard of treatment [27], a neurologi-
cal assessment was daily performed after cardiac arrest
using measures of clinical and electrophysiological eva-
luation. For patients who underwent cooling after resus-
citation, clinical and neurophysiological tests, including
EEG and SSEPs recording, were performed after warm-
ing. For this reason, the findings of the first neurological
assessment reported in results section were recorded
within 24 h-36 h after resuscitation.
Clinical parameters included pupillary light reflex
(present/absent), motor response to painful stimulation
(extensor or absent response/other response), corneal
reflex (present/absent), tonic-clonic seizures (present/
absent) and myoclonus (present/absent).
Electrophysiological assessment included EEG and
Somatosensory-Evoked Potential (SSEP) recordings, rou-
tinely performed in our centre. All EEGs and SSEPs
were read by an expert neurophysiologist (O.E.). Two
EEG were performed: the first within 24 h-36 h after
resuscitation and the second at 72 h. EEGs were
recorded on a system with at least 10 channels and nee-
dle electrodes and used a 10-20 international system
( F p 1 ,F p 2 ,C 3 ,C 4 ,T 5 ,T 6 ,O 1 ,a n dO 2 ) .T h eE E Gp a t -
terns were classified according to the classification sys-
tem of Synek et al. [28,29]. EEG results were categorised
as either malignant (isoelectric, burst-suppression
pattern with interburst interval of at least 1 s and gener-
alised continous epileptiform discharges) or non malig-
nant (other patterns, including alpha and theta coma).
S S E P sw e r ep e r f o r m e da ss o o na sp o s s i b l ea f t e rt h ef i r s t
24 hours after resuscitation. However, if SSEPs record-
ing was due on a weekend day, the recording was post-
poned to Monday. SSEPs were recorded on a Medtronic
keypoint system using 6 channels: erb’point; C6sp; C’3
or C’4, contralateral to the stimulated hand and Fpz
(ipsilateral ear was used as a reference). The 2 remain-
ing channels served as channel controls: C’3-C ’4( o r
C’3-C’4) on which the N20 amplitude was measured,
and Fpz-C’3 (or Fpz-C’4) in order to check for a long
latency component using a larger time window. Absence
of early cortical responses to somatosensory-evoked
potentials (N20) were declared only if the 3 following
conditions were present: (i) correct peripheral (N10) and
medullary (N13) component, (ii) no deflection higher
than 0.5μVo nC 3 - C ’4( o rC ’3-C’4), (iii) no late compo-
nent on Fpz-C’3 (or Fpz-C’4).
Treatment and treatment restriction
All patients were actively supported during the first
days following cardiac arrest or until SSEP assessment.
They received standard intensive care management and
monitoring. In addition, in our practice, therapeutic
hypothermia (target temperature 33°C) was recom-
mended for all cardiac causes of arrest, regardless of
initial rhythm, and left to the assessment of the attend-
ing physician for the other causes. The patients who
underwent cooling received propofol or midazolam and
sufentanyl for sedation and atracurium (0.5 mg/kg per
hour) to prevent shivering. These drugs were stopped
after passive rewarning to a central temperature of
36°C. Hypothermia was induced using an endovascular
cooling catheter (IcyTM, Alsius, Irvine, CA, USA)
inserted into the inferior vena cava via the femoral vein
and connected to a cooling device (Coolgard 3000TM,
Alsius, Irvine, CA, USA), and was maintained for 24 h.
In patients with a bilateral lack of cortical response
(N20) to SSEPs, further treatment was considered futile
and active care was withdrawn. In addition, in accor-
dance with our previous report [27] and recent litera-
ture [1,2,30] a decision to withdraw treatment was
debated by the medical staff after 5 days in patients
w i t h3o rm o r ep e j o r a t i v ec r i t e r i aa t7 2h ;t h e s e
included: absence of pupillary light reflex or corneal
reflex, extensor or absence of motor response to painful
stimulation, persistent myoclonus, and a malignant EEG
pattern
Statistical analysis
Categorical variables were reported as counts and per-
centages. Quantitative data which did not follow a Gaus-
sian curve (NSE levels) were described as median and
Interquartile Range [IQR, first quartile - third quartile].
Other qualitative data were reported as mean ± standard
deviation (SD). Means were compared between two
groups using Student’s t-test, and median levels of NSE
were compared between two groups using the Mann-
Whitney U test. Percentages were compared using a
chi-square test or Fisher exact test for small samples.
The discriminative power of the highest measurement
of NSE in predicting poor outcome at 3 months (CPC
4-5) was evaluated by Receiver Operating Characteristic
(ROC) analysis. Thresholds for NSE are given for 100%
specificity and the highest sensitivity. Area Under the
Curve (AUC) is given with 95% confidence intervals.
Finally, the percentage of abnormal test results, false
positive rates and positive likelihood ratios with their
95% confidence interval were calculated. The positive
likelihood ratio calculation was made possible by adding
0.5 in the cell when there was no patient with a poor
test result and a good outcome [31]. We used EPI-INFO
version 6.04 dfr (EPI-INFO, CDC, Atlanta, GA) for data
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Institute Inc, Cary, NC) for data analysis
Results
Baseline characteristics and neurological outcome
Of the 149 consecutive patients resuscitated after a car-
diac arrest and admitted to the intensive care unit dur-
ing the study period, 97 fulfilled inclusion criteria for
analysis. At 3 months 72 (74%) patients had a poor out-
come (CPC 4-5) and 25 (26%) had a good outcome
(CPC 1-2, n = 17 and CPC 3, n = 8) as shown in Fig-
ure 1. All but one death occurred in the ICU, and in
93% of the cases they were associated with a decision to
withdraw active treatment. In patients (n = 67) for
whom a decision to withdraw active treatment was
taken, the survival median time was 5 days [IQR, 4-8].
As expected in these patients, the survival median time
was lower in patients (n = 45) with unfavorable SSEP
results (4 days [IQR, 3-5]) than in those (n = 22) with
favorable SSEP results (13 days [IQR, 7-20]), p = 0.02.
Patient baseline characteristics are presented in
T a b l e1 .P a t i e n t sw i t hap o o ro u t c o m ew e r eo l d e r ,w i t h
more frequent histories of coronary disease or diabetes
mellitus and had higher disease severity scores at
admission. However, regarding resuscitation time,
there was no difference between patients with a good
or poor outcome, except for primary cause of cardiac
arrest. Sixty-five patients (67%) underwent cooling
after resuscitation: 45 in group CPC 4-5 and 20 in
group CPC 1-3, p = 0.11.
Serum NSE levels and prediction of poor outcome
The median levels of NSE at 24 h (n = 86) and at 72 h
(n = 61) and the highest measurement of NSE for each
patient were significantly higher in patients with poor
outcomes: median 24 h NSE level: 59.4 ng/mL [IQR, 37-
106] versus 28.8 ng/mL [IQR, 18-41] (p < 0.0001); med-
ian 72 h NSE level: 129.5 ng/mL [IQR, 40-247] versus
15.7 ng/mL [IQR, 12-19] (p < 0.0001); and highest mea-
surement of NSE: 87.6 ng/mL [IQR, 44-178] versus 28.8
ng/mL [IQR, 19-41] (p < 0.0001). The frequency of dif-
ferent neurological outcome categories in relation to the
highest individual measurement of NSE concentration of
our patients is presented Figure 2.
Figure 1 Profile of the study.
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NSE for each patient were not different in patients trea-
ted with or without induced hypothermia: 67.4 ng/mL
[IQR, 37.2-143.6] versus 55.3 ng/mL [IQR, 25.1-159.4]
(p = 0.7). In addition, no significant difference for the
highest measurement of NSE was observed in patients
with a good outcome (CPC 1-3) treated with (n = 20) or
without (n = 5) hypothermia; highest measurement of
NSE: 29.6 ng/mL [IQR, 18.7-46.3; Range, 9.7-91.7 ] ver-
sus 19.6 ng/mL [IQR, 8.5-25.5; Range, 8-37.4], p = 0.02,
Table 1 Baseline characteristics
All patients
n=9 7
Poor outcome
n=7 2
Good outcome
n=2 5
p
Age (years), mean ± SD 57 ± 16 60 ± 15 50 ± 17 0.01
Male, n (%) 75 (77) 56 (78) 19 (76) 0.85
Medical history n (%)
Neurologic diseases 11 (11) 10 (14) 1 (4) 0.18
Cardiovascular diseases
Ischemic 20 (21) 19 (26) 1 (4) 0.017
Hypertensive 34 (35) 29 (40) 5 (20) 0.067
Congestive 12 (12) 10 (14) 2 (8) 0.44
Arrhythmic 4 (5) 3 (4) 2 (8) 0.82
Metabolic diseases
Diabetes mellitus 17 (18) 17 (24) 0 0.007
Respiratory diseases
COPD 7 (7) 6 (8) 1 (4) 0.47
Liver diseases
Cirrhosis 4 (4) 4 (6) 0 0.53
Resuscitation variables
Witnessed CA n (%) 77 (79) 57 (79) 20 (80) 0.93
In-hospital CA n (%) 30 (31) 26 (36) 4 (16) 0.06
Primary cause of CA n (%)
Cardiac 55 (57) 38 (53) 17 (68) 0.19
Respiratory 17 (18) 16 (22) 1 (4) 0.04
Other or unknown 22 (23) 17 (24) 5 (20) 0.7
Time from CA to CPR (minutes) 5.6 ± 6.9 6.3 ± 7.2 3.4 ± 5.5 0.07
<3 n (%) 46 (51) 31 (46) 15 (65)
3 -5 n (%) 9 (10) 6 (9) 3 (13)
>5 n (%) 36 (40) 31 (46) 5 (22)
Duration of CPR (minutes) 24.9 ± 24.2 25.7 ± 26.6 22.5 ± 15.7 0.39
<5 n (%) 9 (9) 5 (7) 4 (16)
5 -15 n (%) 18 (19) 13 (18) 5 (20)
>15 n (%) 69 (72) 53 (75) 16 (64)
Primary rhythm n (%) 0.09
Asystole 55 (57) 46 (64) 9 (36)
VF/VT 35 (36) 21 (29) 14 (56)
Pulseless electrical activity 5 (5) 4 (6) 1 (4)
Unknown 2 (2) 1 (1,4) 1 (4)
Number of defibrillations, mean ± SD 2.1 ± 3.1 1.9 ± 3.3 2.8 ± 2.4 0.17
Epinephrine mg mean, ± SD 5.1 ± 5.2 5 ± 4.8 5.6 ± 6.2 0.62
ICU admission
SAPS II mean, ± SD 67 ± 15 69 ± 15 61 ± 11 0.006
Shock n(%) 59 (61) 43 (60) 16 (64) 0.7
Renal replacement therapy n(%) 15 (16) 11(15) 4 (16) 1
MOF n(%) 18 (19) 16 (22) 2 (8) 0.14
Therapeutic hypothermia n(%) 65 (67) 45 (63) 20 (80%) 0.11
CA, cardiac arrest; COPD, chronic obstructive pulmonary disease; CPR, cardiopulmonary resuscitation; FV ventricular fibrillation; MOF, multi organ failure according
to Kraus criteria [27]; SAPS II, Simplified Acute Physiology Score type II; VT, ventricular tachycardia.
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with a poor outcome (CPC 4-5): highest measurement of
NSE in patients (n = 45) treated with hypothermia 105.7
ng/mL [IQR, 48.5-179.7; Range, 16.7-952.3] versus 82.8
ng/mL [IQR, 32.5-172.2; Range, 19.5-1071] in patients (n
= 27) without therapeutic hypothermia p = 0.02.
The ROC curve for poor outcome for the highest
measurement of NSE for each patient is presented in
Figure 3. The NSE level with the highest specificity and
sensitivity was 47 ng/mL (Sp = 84% [95% CI = 70-98],
Se = 72% [95% CI = 62-83]) with a positive predictive
value of 93% [95% CI = 86-100]. An NSE level ≥ 97 ng/
mL predicted a poor outcome with a positive predictive
value of 100% [95% CI = 87-100] and a sensitivity of
49% [95% CI = 37-60]. Interestingly, 32/35 (91%) and
29/35 (83%) of patients with a NSE measurement > 97
ng/mL had unfavorable SSEP results and a malignant
EEG pattern at 72 h, respectively, and the 3 and 6
remaining patients had 3 or more unfavorable clinical
and electrophysiological criteria, respectively (see below).
The sensitivity analysis provided similar results (see
additional file 1: “ Receiver operating characteristic
curves for 72 h NSE value (ng/mL) to predict poor neu-
rological outcome”)
Contribution of each clinical, electrophysiological and
biological test to prediction of poor outcome
The absence of cortical response to SSEPs was
recorded in 45 patients. An unfavorable SSEP result was
associated with 2.9 ± 1 predefined unfavorable clinical-
EEG criteria. In accordance with our treatment restric-
tion policy, all died.
The predictive values of clinical-EEG and biological
tests for a poor outcome are presented in Table 2. An
NSE level ≥ 97 ng/mL (n = 35), myoclonus at 24 h (n =
26), and absence of pupillary light reflex (n = 18) or cor-
neal reflex (n = 31), tonic-clonic seizures (n =6 )a n d
malignant EEG pattern at 72 h (n =3 2 )w e r ep r e d i c t i v e
for a poor outcome with no false positives. Electrophy-
siological and biological tests had a higher percentage of
abnormal test results than clinical tests.
Figure 2 Frequency of different neurological outcome categories in relation to the individual highest measurement of NSE.
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and clinical-EEG tests increased the number of patients
(63/72 (88%)) identified as having a poor outcome, as
shown in Figure 4.
No tests predicted a good outcome. For example, only
51% (24/47) of our patients with a favorable SSEP result
made a good recovery
Discussion
Considering the poor neurological prognosis of coma-
tose patients after cardiac arrest, physicians are rapidly
confronted with the ethical question of whether to con-
tinue intensive treatment. To our knowledge, except for
unfavorable SSEP results, predictors of poor outcome
with a 100% specificity and a high sensitivity are lacking
[1,2,8]. Recently, several studies [2,9-23] have investi-
gated the usefulness of increased serum NSE as a mar-
ker of poor outcome. In this prospective study, we
provide a cut-off value for NSE (> 97 ng/mL), measured
at a fixed time after cardiac arrest, with 100% predictive
value for a poor neurological outcome (death or vegeta-
tive state). However, a strategy based on a combination
of SSEPs, NSE and clinical-EEG tests increase the num-
ber of patients identified as having a poor outcome.
These results may have important implications in deter-
mining the level of care to be provided three days after
cardiac arrest, involving SSEPs or NSE access, and clini-
cal EEG evaluation.
Figure 3 Receiver operating characteristic curves for different peak serum NSE cut-off values (ng/mL) to predict poor neurological
outcome.
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tose after cardiac arrest never regained consciousness.
This result is consistent with previous studies [2,32-36]
and with our recent publication [27] reporting an early
clinical and electrophysiological score with 100% predic-
tive value for poor outcome in this setting. The propor-
tion of patients (49%) with no early cortical responses to
SSEPs, a result recognized to be the most accurate pre-
dictor of a poor outcome in survivors after a cardiac
arrest [2,3,8,34,35,37-39], is also consistent with previous
reports [2,27,34-36]. We also report that an unfavorable
SSEP result was associated with a mean of 2.9 ± 1 other
pejorative clinical-EEG criteria. In addition, our results
confirm that the presence of early cortical responses to
SSEPs is a poor predictor of a good outcome, as pre-
viously reported [2,27,34,40]; indeed, only 51% (24/47) of
our patients with a favorable SSEP result made a good
recovery. Interestingly, we report that the absence of
motor response to painful stimuli has a higher false posi-
tive poor outcome prediction compared to the American
Academy of Neurology (AAN) meta-analysis [1] and that
a malignant EEG is strongly associated with outcome.
These findings are consistent with a recent report [41]
assessing the prognostic value of clinical and electrophy-
siological variables in comatose survivors of cardiac arrest
treated with therapeutic hypothermia and suggest using
caution in the application of AAN guidelines.
NSE levels were significantly higher in comatose car-
diac arrest survivors with poor outcome, regardless of
the time of measurement. In addition, we identified a
cut-off value for NSE (> 97 ng/mL), predicting a poor
outcome (death or vegetative state) with no false posi-
tives. Interestingly, 32/35 (91%) and 29/35 (83%)
patients with an NSE measurement > 97 ng/mL had an
unfavorable SSEP result and a malignant EEG pattern at
72 h, respectively. These findings argue that NSE mea-
surement may be used, in combination with clinical
tests, as a potential substitute for SSEPs and EEG in set-
tings without access to electrophysiological assessment,
for early identification of a subgroup of irrecoverable
patients for whom continued intensive care could be
considered futile.
Table 2 Prediction of poor outcome with clinical, electrophysiological and biological variables
Patients
tested, n
Abnormal test result, %
(95% CI)
False positive rate*, %
(95% IC)
Positive likelihood ratio
(95% IC)
Motor response ≤ 2
- 24 h-36 h 97 87% [80% - 93%] 56% [45%- 67% 1.7 [1.2 - 2.5]
- 72 h 87 70% [61% - 80%] 16% [7% - 25%] 5.8 [2.3 -1 4.1]
No corneal reflexes
- 24 h-36 h 95 40% [30% - 50%] 12% [2% - 22%] 4.2 [1.4 - 12.4]
- 72 h 86 36% [26% - 46%] 0% [0%-14%] 26 [1.7 - 415]
No pupillary reflexes
- 24 h-36 h 97 26% [17% - 35%] 4% [4% - 12%] 8.3 [1.2 - 58]
- 72 h 87 21% [12% - 29%] 0% [0% - 14%] 15 [1 - 244]
Myoclonus
- 24 h-36 h 97 27% [18% - 36%] 0% [0% -14%] 19 [1.2 - 299]
- 72 h 87 23% [14% - 32%] 8% [4% - 20%] 3.6 [1-14]
Epilepsy
- 24 h-36 h 97 7% [7% - 12%] 0% [0% -14%] 5.3 [0.3-90]
- 72 h 87 7% [2% - 12%] 0% [0% -14%] 5.3 [0.31-91]
- Malignant EEG **
- 24-36 h 90
¶ 44% [34% - 55%] 4% [2% - 10%] 14 [2.1-97]
-7 2h 7 3
¶¶ 44% [33% - 55%] 0% [0% -17%] 25 [1.6-394]
Highest measurement of NSE ≥ 47
ng/mL
97 58% [48% - 68%] 7% [0,4% - 14%] 4.5 [1.8 -11]
Highest measurement of NSE ≥ 97
ng/mL
97 36% [27% - 46%] 0% [0% -13%] 25 [1.6-397]
* Patients with abnormal test results and good outcome/all patients with abnormal test results (1-positive predictive value)
** included isoelectric and burst-suppression pattern with interburst interval of at least 1s and generalised continuous epileptiform discharges
¶ Forty-four patients were still affected by sedative medication
¶¶ twenty-one patients were still affected by sedative medication
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dictive value of poor outcome determined in our study
is rather high in comparison with others (range 9 to 91
ng/mL) previously reported (Table 3). Differences in
selected patients (outside- or inside-hospital resuscita-
tion, primary cause of cardiac arrest, initial rhythm, time
of inclusion after cardiac arrest), definitions of poor
outcome (death, Glasgow Coma Scale < 8, absence of
regaining of consciousness (CPC 4-5) or without return
to normal social activity (CPC 3-5)), duration of follow
up (hospital discharge, 1-month, 3-month or 6-month),
time of blood sampling and assay procedures could
explain these differences. Nevertheless, we consider that
a poor outcome defined by CPC 4-5 is more accurate in
a study assessing a cut-off value of a biomarker on
which treatment withdrawal could be decided. In this
context, except for references [2] and [10], cut-off values
for NSE are highest (range 39 to 91 ng/mL) in studies
[15-19] with vegetative state or death as endpoints, in
accordance with our results.
Whether hypothermia, performed in most of our
patients, may affect NSE measurement is unclear.
Recently, studies [9,20] testing the predictive values for
NSE to predict poor outcome (CPC 3-5) in comatose
patients after cardiac arrest treated with therapeutic
hypothermia, reported cut-off values for NSE, at 48 h, of
28 ng/mL and 33 ng/mL, respectively; a result no
different from that reported by Zandbergen et al. in
patients without therapeutic hypothermia [2]. In con-
trast, hypothermic therapy for prevention of hypoxic
damage after cardiac arrest has been reported to
decrease NSE levels in comparison with levels with nor-
mothermic therapy [14,42]. However, in these studies
[14,42], the cut-off values for NSE predicting a poor
outcome (CPC 3-5) were significantly higher in patients
treated with induced hypothermia than in patients with-
out therapeutic hypothermia. In this setting, NSE levels
were higher (but not significantly) in patients treated
with induced hypothermia.
Therefore, considering decisions to continue treatment
in comatose patients after cardiac arrest, the different
cut-off values for NSE reported in the literature should
be interpreted with caution as many patient, treatment,
and assay-procedure related factors may influence NSE
measurement. For example, if we had used the NSE
t h r e s h o l d>3 3n g / m L ,d e f i n e db yZ a n d b e r g e ne ta l .[ 2 ]
to withdraw treatment in patients remaining comatose
24 h after cardiac arrest, 10/25 (40%) of our patients
with a good outcome could have had false predictions
of a poor outcome (death or vegetative state).
We also report that an approach based on a combina-
tion of electrophysiological, biological and clinical tests
allowed to increase the number of patients identified as
having a poor outcome (Figure 3), in accordance with
Figure 4 Predictors of poor outcome according to different clinical-EEG, NSE and SSEPs combinations. * included: myoclonus at 24 h,
and absence of pupillary light reflex or corneal reflex, tonic-clonic seizures and malignant EEG pattern at 72 h.
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Page 9 of 13Table 3 Comparison of NSE levels to predict poor outcome after cardiac arrest and referenced study profiles
Référence In-
hospital
CPR (%)
Time of
inclusion
after CPR,
n
Hypothermic
therapy,
n
Follow-
up
Poor outcome
definition, and
number
n
Method used for NSE
measurement
NSE
sampling
time
Cut-off
value
(ng/mL)
Se Sp
Fogel et al.
[10] 1997
Not
specified
ICU
admission
n=4 3
No 3
months
Remained
comatose
n=2 5
Radioimmunoassay,
Pharmacia LKB
Day 0
Day 1
Day 2
Day 3
33
33
33
33
25
60
63
65
100
100
100
100
Martens et al.
[21] 1998
Not
specified
>2 4h
n=6 4
No 6
months
Remained
comatose
n=3 5
Radioimmunoassay,
Profilogen
24 h 20 51 89
Schoerkhber
et al. [11]
1999
Yes (not
specified)
>6h
n=5 6
No 6
months
CPC 3-5
n=2 8
Radioimmunoassay,
Profilogen
12 h
24 h
48 h
72 h
Peak NSE
level 12-
72 h
38
40
25
17
27
18
8
48
70
29
100
100
100
100
100
Rosen et al.
[12] 2001
No > 24 h
n=6 6
No 1 year CPC 3-5
n=4 2
Imunoluminometric assay,
Byk Sangtec Diagnostica
Day1
Day2
Day3
25
25
25
NM
NM
NM
100
100
100
Zingler et al.
[15]2003
Yes (not
specified)
ICU
admission
n=2 7
No 3
months
CPC 4-5
n=1 7
Immunoluminometric
assay, Byk Sangtec
Diagnostica
Day1
Day2
Day3
Day7
48
43
91
39
53
91
75
57
100
100
100
100
Tiainem et al.
[14] 2003
No* ICU
admission
n=7 0
Yes
n=3 6
6
months
CPC 3-5
n=2 9
time-resolved
immunofluorometric assay
(DELFIA, Wallac)
24 h HT/
no HT
36 h HT/
no HT
48 h HT/
no HT
31/13
26/13
25/9
22/
59
30/
63
25/
76
96/
100
96/
100
96/
100
Meynaar et
al.
[13] 2003
Yes
(23%)
ICU
admission
n = 110
No Hospital
discharge
Remained
comatose
n=8 1
time-resolved
immunofluorometric assay
(DELFIA, Wallac)
Peak NSE
level 24-
48 h¶
25 59 100
Pfeifer et al.
[16]2005
Yes
(44%)
>4 8h
n=9 7
Not specified Day 28 CPC 4-5
n=7 0
Imunoluminometric assays,
Byk Sangtec Diagnostica
Day 3 65 50 96
Rech at al.
[17]2006
Yes
(100%)
>12 h
n=4 5
No 6
months
CPC 4-5
n=3 4
Electrochemiluminescence
immunoassay, Roche
Mannheim
Between
12-36 h
60 35 100
Zandbergen
et al
[2]2006
Not
specified
>2 4h
n = 407
Yes (not
specified)
1
months
CPC 4-5
n = 356
Immunoluminometric
assay, Byk Sangtec
Diagnostica
24 h
48 h
72 h
>33
>33
>33
42
52
46
100
100
100
Auer et al.
[18] 2006
Yes (not
specified)
n = 17 Not specified Hospital
discharge
Death
n=9
Electrochemiluminescence
immunoassay, Roche
Mannheim
48 h 30 79 100
Grubb et al.
[23] 2007
No ICU
admission
n = 143
Not specified Hospital
discharge
Death Enzyme immunoassay,
Roche Diagnostics
12 h
24-48 h
72-96 h
NM
71
NM
14 100
Reisinger et
al.
[19]2007
Yes
(44%)
ICU
admission
n = 177
Yes
n=2 0
6
months
CPC 4-5
n=5 9
Electrochemiluminescence
immunoassay, Roche
Mannheim
Peak NSE
level
Day 0-4
80 63 100
Oksanen et
al.
[20] 2009
No* ICU
admission
n=9 0
Yes
n=9 0
6
months
CPC 3-5
n=4 0
Electrochemiluminescence
immunoassay, Roche
Mannheim
24 h
48 h
41
33
20
43
100
100
Rundgren et
al.
[9] 2009
Yes
(17%)
ICU
admission
n = 102
(for NSE
cohort)
Yes
n = 102
6
months
CPC 3-5
n=4 6
Imunoluminometric assay,
DiaSorin
2h
24 h
48 h
72 h
31
38
28
27
6
11
67
50
100
100
100
100
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Page 10 of 13other studies [2,8,13,15,16,19,27]. Therefore, based on all
available evidence [1-24,27,30,32-40] and our current
results, we suggest the following strategy to help clini-
cians determine the level of care to be provided in
patients remaining comatose three days after cardiac
arrest: when the cortical response (N20) to SSEPs is
bilaterally absent, further treatment should be consid-
ered futile and active care withdrawn. When the SSEP
recording is equivocal, it must be repeated. When SSEPs
are favourable or when SSEPs are not accessible, the
presence of more than one pejorative EEG-biological-
clinical criterion at day 3 should be considered sufficient
to forego further treatment; these include: serum NSE >
97 ng/mL, malignant EEG pattern (burst-suppression
with or without epileptiform discharge or isoelectric pat-
tern), absence of pupillary light reflex or corneal reflex,
and persistence of tonic-clonic seizures or myoclonus.
Moreover, we would like to emphasize that no tests are
available that can reliably predict recovery of conscious-
ness or the quality of life in survivors. Nevertheless, a
recent study reported that continuous amplitude-inte-
grated electroencephalogram added valuable positive
and negative prognostic information in hypothermia-
treated cardiac arrest patients [43].
This study has some limitations. Firstly, the relative
small sample size may limit the interpretation and rele-
vance of the cut-off value for NSE. In addition, because
of differences in NSE measurements obtained using
assays from different manufacturers (Table 3), the cut-
off values for NSE reported in this setting should be
interpreted with caution. Secondly, hemolysis due to
renal replacement therapy needed for 15 patients at ICU
admission may affect the cut-off value for NSE. How-
ever, we believe the effect of this hemolysis was limited
because the highest measurement of NSE was signifi-
cantly lower in patients with renal replacement therapy
(59 ng/mL [IQR, 35-112] versus 67 ng/mL [IQR, 34-
159], p = 0.025). Thirdly, the applicability of our find-
ings could be limited because of early withdrawal of
treatment for patients with poor prognoses, which could
result in a self-fulfilling prophesy of poor outcome.
However, all of our patients were actively supported
without restriction during the first days following car-
diac arrest or until SSEPs were assessed, and only a lack
of bilateral cortical response to SSEPs associated with
pejorative clinical-EEG criteria in all cases in our study,
or the presence of 3 or more predefined pejorative clini-
cal-EEG criteria, recognised to predict a worse outcome
[1,2,30], could lead to active care withdrawal. In addi-
tion, because our study focuses specifically on comatose
patients after cardiac arrest for whom there is an ethical
question of whether to continue treatment, we believe
that this report adds useful information about clinical
outcome and predictors of death or vegetative state in
this setting.
Conclusion
We show that NSE levels, measured early in the course
of patient care for those who remained comatose 3 days
after cardiac arrest, are significantly higher in patients
with a poor outcome (death or vegetative state). In addi-
tion, we provide a cut-off value (> 97 ng/mL) for NSE,
with 100% predictive value for a poor outcome. Never-
theless, considering decisions to continue treatment in
this setting, we emphasize that cut-off values for NSE
presented in the literature should be interpreted with
caution and that an approach based on a combination
of SSEPs, NSE and clinical-EEG tests would be the most
accurate for early identification of a subgroup of irrecov-
erable patients for whom intensive treatment could be
regarded as futile and palliative care only could be
provided.
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Table 3 Comparison of NSE levels to predict poor outcome after cardiac arrest and referenced study profiles
(Continued)
Shinozaki et
al.
[22] 2009
Yes
(27%)
ICU
admission
n=8 0
Yes
n=4 5
6
months
CPC 3-5
n=6 7
Immunoradiometric assay,
Profilogen, DiaSorin
Admission
6h
24 h
46
66
40
14
19
72
100
100
100
Steffen et al
[42] 2010
Yes
(21%)
ICU
admission
n = 240
Yes
n = 133
ICU
discharge
CPC 3-5
n = 147
Electrochemiluminescence
immunoassay, Roche
Mannheim
72 h HT/
no HT
79/27 50
80
100
100
Present
study
Yes
(31%)
>4 8h
n=9 7
Yes
n=6 5
3
months
CPC 4-5
n=7 2
Electrochemiluminescence
immunoassay, Roche
Mannheim
Peak NSE
level 24-
72 h
97 49 100
HT; hypothermic therapy, NM; not mentioned
* Only ventricular fibrillation as initial rhythm was eligible for the study
¶ Results mentioned only for patients who remained comatose 48 hours after CPR (n = 67)
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Page 11 of 13Additional material
Additional file 1: “ Receiver operating characteristic curves for 72 h
NSE values (ng/mL) to predict poor neurological outcome. This file
highlight that considering 72 h-NSE values (n = 61), a level ≥ 68 ng/mL
predicted a poor outcome (CPC 4-5) with a positive predictive value of
100% [95% IC = 100% - 100%] and a sensitivity of 67% [95% IC = 54% -
81%].
Abbreviations
EEG: Electro-Encephalography; GPCPC: Glasgow-Pittsburgh Cerebral
Performance Category; NSE: Neuron-Specific Enolase; SSEPs: Somatosensory
Evoked Potentials; ROC: Receiver Operating Characteristics.
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